DE60310767T2 - PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN - Google Patents

PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN Download PDF

Info

Publication number
DE60310767T2
DE60310767T2 DE60310767T DE60310767T DE60310767T2 DE 60310767 T2 DE60310767 T2 DE 60310767T2 DE 60310767 T DE60310767 T DE 60310767T DE 60310767 T DE60310767 T DE 60310767T DE 60310767 T2 DE60310767 T2 DE 60310767T2
Authority
DE
Germany
Prior art keywords
alkyl
het
methyl
optionally substituted
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60310767T
Other languages
German (de)
English (en)
Other versions
DE60310767D1 (de
Inventor
Gregory Waltham Basarab
Joseph Waltham Eyermann
Madhusudhan Waltham Govravaram
Oluyinka Waltham Green
Lawrence Waltham MacPherson
Marshall Waltham Morningstar
Thanh San Diego NGUYEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60310767D1 publication Critical patent/DE60310767D1/de
Application granted granted Critical
Publication of DE60310767T2 publication Critical patent/DE60310767T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60310767T 2002-12-20 2003-12-19 PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN Expired - Fee Related DE60310767T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0203825 2002-12-20
SE0203825A SE0203825D0 (sv) 2002-12-20 2002-12-20 Novel fused heterocycles and uses thereof
PCT/SE2003/002033 WO2004056831A1 (en) 2002-12-20 2003-12-19 PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION

Publications (2)

Publication Number Publication Date
DE60310767D1 DE60310767D1 (de) 2007-02-08
DE60310767T2 true DE60310767T2 (de) 2007-10-11

Family

ID=20289974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60310767T Expired - Fee Related DE60310767T2 (de) 2002-12-20 2003-12-19 PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN

Country Status (9)

Country Link
US (1) US20070004761A1 (cg-RX-API-DMAC7.html)
EP (1) EP1585748B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006512366A (cg-RX-API-DMAC7.html)
AT (1) ATE349448T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003288869A1 (cg-RX-API-DMAC7.html)
DE (1) DE60310767T2 (cg-RX-API-DMAC7.html)
ES (1) ES2278211T3 (cg-RX-API-DMAC7.html)
SE (1) SE0203825D0 (cg-RX-API-DMAC7.html)
WO (1) WO2004056831A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160307A0 (en) 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US9255099B2 (en) 2006-06-06 2016-02-09 Intra-Cellular Therapies, Inc. Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors
JP2010509399A (ja) 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
AU2008331833A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体拮抗薬としてのインダゾール化合物
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1アンタゴニストとしてのピラゾール化合物
KR20110060904A (ko) 2008-09-26 2011-06-08 베링거 인겔하임 인터내셔날 게엠베하 Ccr1 수용체 길항제로서의 아자인다졸 화합물
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
GEP20146029B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
US8927556B2 (en) 2008-12-06 2015-01-06 Intra-Cellular Therapies, Inc. 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
RS53130B (sr) 2009-10-21 2014-06-30 Boehringer Ingelheim International Gmbh Jedinjenja indazola i pirazolopiridina kao ccr1 receptor antagonisti
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしての複素環化合物
MX2012006524A (es) * 2009-12-08 2012-07-17 Boehringer Ingelheim Int Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US11786528B2 (en) 2018-06-04 2023-10-17 Exscientia Ltd. Pyrazolopyrimidine compounds as adenosine receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3839839A1 (de) * 1988-11-25 1990-05-31 Henning Berlin Gmbh Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen
SE0102315D0 (sv) * 2001-06-28 2001-06-28 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
ES2278211T3 (es) 2007-08-01
ATE349448T1 (de) 2007-01-15
JP2006512366A (ja) 2006-04-13
EP1585748B1 (en) 2006-12-27
EP1585748A1 (en) 2005-10-19
US20070004761A1 (en) 2007-01-04
AU2003288869A1 (en) 2004-07-14
DE60310767D1 (de) 2007-02-08
SE0203825D0 (sv) 2002-12-20
WO2004056831A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
DE60310767T2 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
US7371757B2 (en) Fused heterocycles as inhibitors of glutamate racemase(MURI)
DE60124577T2 (de) Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
DE60021630T2 (de) Tricyclische kondensierte heterocyclische Verbindungen als CRF Antagonisten
EP1611133B1 (en) Condensed n-heterocyclic compound and use thereoff as crf receptor antagonist
EP3166608B1 (en) Aminopyridazinone compounds as protein kinase inhibitors
DE60315615T2 (de) Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
DE60319820T2 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
DE69609602T2 (de) Pyrazolderivate und verfahren zu deren herstellung
EP2773623B1 (en) 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
DE602004005960T2 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
DE19629652A1 (de) 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE60209721T2 (de) Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
DE60103909T2 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DD297819A5 (de) Verfahren zur herstellung von 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidinderivaten
DE69601527T2 (de) Pyrrolylbenzimidazol-Derivate
CN116685585A (zh) 一种高活性的hpk1激酶抑制剂
DE69226157T2 (de) Antiallergische, entzündungshemmende und anti-PAF Pyridazinverbindungen
CN115260193A (zh) 用于治疗狂犬病的化合物及其方法
DE60104130T2 (de) 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate
DE60026883T2 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
EP2558465B1 (de) Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
EP0621037A1 (de) Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE2215440A1 (de) l.S-Dihydro-S-hydroxyo-phenyWH-i^benzodiazepin-2-on-substituierteDiaminoacetate und ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69121894T2 (de) Heterocyclische verbindungen, herstellung und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee